Glucagon-like peptide-1 (glp-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials

HIGHLIGHTS

• who: Jing Qin from the Department of Emergency, The Second hospital of Lanzhou University, Lanzhou, China have published the paper: Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials, in the Journal: (JOURNAL)
• what: The aim of this study was to evaluate the risk of cardiovascular events of GLP-1 (albiglutide exenatide liraglutide semaglutide lixisenatide and dulaglutide) receptor agonists in T2DM patients.
• how: The results indicated that GLP-1 receptor agonists reduced the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.